Please assess the completion status of the following clinical trial:

Trial Title: Concentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with hematological malignancies who were going to receive a CVC for intensive chemotherapy including patients for stem cell transplantation~* written informed consent~* 18 years or older~Exclusion Criteria:~* the presence of a central venous catheter at admission~* history of central venous catheter related thrombosis or infection~* indication for anticoagulant treatment or prophylaxis~* patients with totally implanted catheters~* catheters impregnated with antimicrobial agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: heparin (Heparin LEO) (Type: ACTIVE_COMPARATOR): After each use, the central venous catheter lumen will be flushed with 10 ml 0.9% NaCl and then locked with heparin 5000 IU/ml(standard treatment)using a volume exactly equivalent to the internal volume noted on each catheter.
- B: concentrated citrate (Citralock) (Type: EXPERIMENTAL): locking the central venous catheter with concentrated citrate after each use

Based on this trial design, predict the completion outcome and termination type (if applicable).